AstraZeneca Beats Earnings Expectations with Cancer Drug Sales
AstraZeneca’s stock rose sharply on Tuesday after the company reported better-than-expected sales for its fourth-quarter earnings. The boost came from strong sales of several cancer drugs, including Tagrisso and Calquence, which treat lung cancer, leukemia, and lymphoma. Tagrisso saw revenue exceed expectations at $1.9 billion, driven by uptake in all types of patients across different … Read more